- Home
- PRME
PRME
Prime Medicine Inc.
as 05-15-2025 10:42am EST
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | N/A | IPO Year: | 2022 |
| Target Price: | $13.17 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.11 - $8.27 | Next Earning Date: | 05-08-2025 |
| Revenue: | $3,846,000 | Revenue Growth: | 550.76% |
| Revenue Growth (this year): | 56.92% | Revenue Growth (next year): | 150.59% |
Latest Prime Medicine Inc. News
PRME Breaking Stock News: Dive into PRME Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
GlobeNewswire
7 days ago
Prime Medicine Reports First Quarter 2025 Financial Results and Provides Business Updates
TipRanks
a month ago
Biotech stocks slide as Marks resignation seen being negative for sector
Motley Fool
2 months ago
Why Prime Medicine Stock Was Climbing Higher This Week
MT Newswires
2 months ago
Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating
Motley Fool
2 months ago
Why Prime Medicine Stock Is Soaring Today
BioPharma Dive
2 months ago
Prime sets sights on liver, lung disease as next target for its gene editing tech
MT Newswires
2 months ago
Prime Medicine Launches Preclinical Program for Liver Treatments
Compare PRME vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRME Prime Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.